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Abstract 
Schistosomes are blood parasites adapted to their intravascular habitat that have 
evolved mechanisms to evade the immune and haemostatic responses of their hosts. It 
has been observed that the schistosome can regulate the endothelium function along the 
infection, which contributes to modulation of host defensive responses and parasite 
survival. The purpose of this work was the analysis of the changes induced by S. bovis 
adult worms in the proteome expressed by infected mice on the endothelial surface of 
their portal vein. With this aim, we have utilized a methodology that allows the 
purification, identification and relative quantification of endothelial cell surface proteins 
after their selective in vivo labeling with biotin. Trypsin digestion of the biotinylated 
proteins and subsequent liquid chromatography and tandem mass spectrometry analysis 
(LC-MS/MS) resulted in the identification of a total 127 non redundant proteins. All 
these proteins have been classified according to their function and cellular location, and 
the differences between S. bovis-infected and non-infected mice in their endothelial 
surface proteomes have been analyzed. The present work provides the first data on the 
proteome of the endothelial surface of the portal vein, and identifies some of the 
changes induced in it after an infection by S. bovis.  
Keywords: Schistosoma bovis; vascular endothelium; biotinylation; mass spectrometry; 
proteome.   
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1. Introduction. 
Animal schistosomiasis, caused by Schistosoma bovis, is a serious veterinary 
problem, affecting large numbers of animals and causing significant economic losses to 
farmers in many areas of the world. S. bovis, a close relative to human schistosome S. 
haematobium [1], lives in the mesenteric veins of its host and is distributed across 
almost the whole of Africa and south western Asia, where it has been estimated that 
there are 165 million of infected animals. In Europe it is present on the Mediterranean 
islands and in Spain [2]. 
Schistosome cercariae infect their vertebrate hosts through the skin. Then, they 
enter the blood circulation, performing an intra-organic migration along which they 
mature and reach their final localization (portal vein and mesenteric vessels for S. 
bovis), where they transform into adults and live for years. During its migration through 
the host, larvae of the parasite migrate through the blood vessels of several organs and 
tissues, including the subcutaneous tissue, the lungs, heart, the portal hepatic system and 
mesenteric veins, where they interacts with vascular endothelial cells [3, 4]. This 
interaction occurs through the tegument surface and through the suckers of the worm, 
which are used to adhere to the vessel wall. Additionally, the vascular endothelium 
interacts with the products released by the parasites, namely, components shed from the 
tegument and excretion-secretion products. 
The vascular endothelium is a smooth surface formed by a monolayer of cells that 
acts as a semipermeable barrier between the lumen of blood vessels (arteries, veins and 
capillaries) and the surrounding tissues. The endothelium regulates vascular tone and 
permeability, coagulation and thrombosis, and governs the passage of leukocytes 
towards areas of inflammation through the expression of surface proteins and the 
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secretion of soluble mediators [5, 6]. Additionally, endothelial cells are the targets of 
cytokines that alter cell function during inflammation [7, 8]. 
Schistosomes are perfectly adapted to their intravascular habitat and have evolved 
mechanisms to evade the immune and haemostatic responses of their hosts [9-12]. In 
this context, it has been observed that parasite molecules can regulate the function of the 
endothelium along the infection, which contributes to the modulation of host defensive 
responses and parasite survival. Some in vitro studies have shown that the products 
secreted by the schistosomula of S. mansoni limit inflammation through the induction of 
IL-6 and down regulation of the adhesion molecules E-selectin and VCAM-1 in 
endothelial cells, thereby avoiding the immune/inflammatory response during their 
transit through the lungs [13-15]. It has also been found that the adult worms of the 
same species exert a regulatory effect on the release of nitric oxide [16]. More recently, 
studies performed with endothelial cell cultures from mesenteric microvasculature have 
demonstrated that schistosomes increase vascular permeability and endothelial cell-
leukocyte interactions, and that these effects are partially caused by a decrease in the 
expression of endothelial NO synthase (eNOS) [17]. In addition, S. mansoni infections 
are known to produce an increase in the plasma concentration of the soluble form of 
ICAM-1, a classic marker of endothelial activation in inflammation, which correlates 
with the severity of the disease [18].  
In spite of the above, and in light of the importance of the regulation of endothelial 
function in schistosome infections, studies dealing with schistosome-endothelium 
interactions are very scant, and their results are sometimes contradictory [17]. 
Additionally, little information is available concerning the changes that they produce on 
the surface of the endothelium along infection, and there is also a lack of information 
regarding the parasite molecules involved in such a regulation. 
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Accordingly, in the present work we were prompted to investigate the proteome of 
the endothelial surface of the portal vein expressed as a result of the presence of adult 
worms. To accomplish this, we used a methodology consisting of the vascular perfusion 
of mice (infected and not with S. bovis) with a biotin ester reactive. In this way the 
endothelial surface proteins showing free amino groups would become biotinylated and 
efficiently purified by streptavidin affinity chromatography. Trypsin digestion of 
biotinylated proteins and subsequent liquid chromatography and tandem mass 
spectrometry analysis (LC-MS/MS) resulted in the identification of a total of 127 
proteins in hepatic portal vein endothelium from S. bovis-infected and non-infected 
mice. The proteins were classified according to their biological function and cellular 
location, and the differences between the infected and non-infected mice in their 
endothelial surface proteomes were analyzed.  
 
2. Material and Methods 
2.1. Experimental animals and infection protocol.  
Forty NMRI mice weighing 30-35 g (Harlan Laboratories Models, S.L.) were 
used. The mice were distributed in the following experimental groups: R0 (control 
group, n= 10), non-infected mice, perfused with buffer; R1 (n= 15), non-infected mice, 
perfused with biotin; R2 (n= 15), mice infected with S. bovis and perfused with biotin. 
All mice were subjected to the same surgical and perfusion procedure, as described 
below. 
Mouse infection with S. bovis (R2 group) was done by tail immersion with 200 
S. bovis cercariae for 60 min. Four months later, when the infections were fully 
established, the animals were perfused with sulfo-NHS-LC-biotin.  
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All animal manipulations were done according to the rules from the ethical and 
animal welfare Committee from the Institution where the experiments were conducted 
(IRNASA, CSIC), following the corresponding EU rules and regulations. 
 
2.2. Perfusion procedure for in vivo biotinylation. 
We followed the procedure for in vivo perfusion described by Roesli et al. [19]. 
The mice were anesthetized with a combined subcutaneous injection of 200 
mg/kg ketamine (Imalgene 1000, Merial) and 20 mg/kg xylazine (Xilagesic 2%, 
Laboratories Calier, S.A.). The chests of the anesthetized mice were opened through a 
median sternotomy. Perfusion was performed from the aorta through the hepatic portal 
system. To do this, a perfusion needle (24-gauge catheter, BD Insyte) was inserted into 
the aortic artery at the exit from the left ventricle, through which the solutions were 
administered and another catheter was inserted at the posterior end of the portal vein to 
allow outflow of the perfusion solutions. Blood components were washed away with 
pre-warmed PBS (38ºC) supplemented with 10% dextran 40 (Sigma) as a plasma 
expander for 10 min. Immediately afterwards, the mice were perfused with 10 ml of 
biotinylation solution at a flow rate of 1 ml/min. The perfusion solution contained 1 
mg/ml of sulfo-NHS-LC-biotin (Thermo Scientific) in PBS (pH 7.4, 38 ºC) and 10% of 
dextran 40. To prevent hydrolysis of the sulfo-NHS-LC-biotin, the reagent was 
dissolved immediately before the beginning of the in vivo perfusion. Subsequently, to 
neutralize unreacted biotinylation reagent the mice were then perfused for 10 min with 
50 mM Tris-HCl in PBS and 10% dextran 40. Mice in the R0 control group were 
perfused as above, except without the addition of sulfo-NHS-LC-biotin to the perfusion 
solution. During perfusion with the biotinylation solution the abdomens of the animals 
were wetted with a quenching solution (50 mM Tris-HCl in PBS, pH 7.4, 38ºC) to avoid 
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the biotinylation of organ surfaces. All the solutions were perfused using a peristaltic 
pump and the flow rate was tuned so as not to exceed a counter pressure of 100 mmHg. 
Throughout the operation, the mice remained fixed to a solid surface, which was 
slightly inclined to help the drainage of excess liquid, and were kept warm (38ºC) with 
the aid of a lamp. 
After perfusion, a sample of the portal vein through which the perfused solutions 
had passed was excised and the specimen was either freshly snap-frozen for the 
preparation of organ homogenates or fixed during 24 hours in 4% saline formaldehyde 
for histochemical analysis.  
 
2.3. Protein extraction and purification. 
In all groups, the samples of portal vein were processed in batches of 4 mice. 
Hepatic portal vein samples were resuspended in lysis buffer (2% SDS, 50 mM Tris, 10 
mM EDTA, complete EDTA-free proteinase inhibitor cocktail (Roche Diagnostics) in 
PBS, pH 6.8.) at a ratio of 40 µl of buffer per mg of sample. The samples were 
homogenized six times using an Ultra-Turrax T10 disperser (IKA-Werke), 2 min each 
at full power. The homogenates were sonicated for 3 min, incubated at 95 ºC for 20 min 
and, after cooling to room temperature, centrifuged at 17,000 g for 20 min. Then, to 
eliminate as much SDS as possible and to avoid interference in biotin-streptavidin 
binding, the supernatant was dialyzed with PBS for 24 hours. The concentration of the 
total protein extract of the supernatant was determined using the BCA Protein Assay 
Reagent kit (Pierce). 
Biotinylated proteins from this extract were purified by affinity chromatography 
using a streptavidin-sepharose resin (GE Healthcare). The slurry resin was washed three 
times in a buffer containing 1% Nonidet P-40 and 0.1% SDS in PBS (pH 7.4). Five mg 
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of total protein extract was added to 215 µl of resin and biotinylated proteins were 
captured for 2 h at room temperature in a revolving mixer at low rotation speed. The 
unbound proteins were eliminated by washing 3 times with the above-mentioned buffer 
and centrifugation at 470 g. 
 
2.4. On-resin tryptic digestion 
The resin with the bound biotinylated protein was washed three times with 400 
µl of 50 mM NH4HCO3. Following this, proteins were digested overnight at 37 ºC with 
2 µg of sequencing grade trypsin (Promega) in a total volume of 400 µl of 50 mM 
NH4HCO3. The reaction was stopped with 20 µl of 10% trifluoroacetic acid (TFA), after 
which the digestion mixture was collected by centrifugation and the resin was washed 
once with 200 µl of 5% acetonitrile and 0.1% TFA in water. All the fractions combined 
were dried in a vacuum centrifuge and resuspended in 200 µl of 5% acetonitrile and 
0.1% TFA. Tryptic peptide samples were analysed by liquid chromatography-tandem 
mass spectrometry. 
The concentration of the peptides was estimated by UV spectrometry, assuming 
that a 1 mg/ml solution of proteins has an extinction of 1.1 absorbance units at 280 nm. 
 
2.5. Liquid chromatography and tandem mass spectrometry (LC-MS/MS). 
For the R1 and R2 groups, two independent batches of four portal vein samples 
each were subjected to LC-MS/MS. For the control group (R0), one batch of four portal 
vein samples was subjected to LC-MS/MS. For all the samples, two technical replicas 
of the chromatogram were performed. 
Peptide separation by LC-MS/MS was performed using an Ultimate nano-LC 
system (LC Packings) and a QSTAR XL Q-TOF hybrid mass spectrometer (ABSciex). 
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LC-MS/MS was performed as described before by De la Torre-Escudero et al. 
[20] with some modifications. Briefly, an aliquot corresponding to 5 µl containing 3.9 
µg of digested peptides was loaded onto a trap column (PepMap C18, 300 μm×5 mm, 
LC Packings) and desalted with 0.1% TFA at 30 μl/min for 3 min. The peptides were 
then loaded onto an analytical column (PepMap C18 3 μ 100 Å, 75 μm×15 mm, LC 
Packings) equilibrated in 5% acetonitrile and 0.1% formic acid. Elution was carried out 
with a linear 2-30% gradient of 95% acetonitrile and 0.1% formic acid over 110 min at 
a flow rate of 300 μl/min. The peptides eluted were analyzed with a nanoESI-Q-TOF 
mass spectrometer (QSTAR-XL, AB Sciex) in information-dependent acquisition mode 
(IDA), in which a 1-s TOF MS scan from 400–2000 m/z was performed, followed by 3-
s product ion scans from 65–2000 m/z on the three most intense doubly or triply 
charged ions. 
 
2.6. Database search and protein identification. 
 Database searches were performed in the NCBInr Mus musculus database 
(17005982 sequences; 5838490176 residues) using MASCOT v2.2 (Matrix Science) 
and ProteinPilot v4.0 (AB Sciex) search engines. For samples from the R2 group, an 
additional search was performed using MASCOT v2.2 in a custom made Schistosoma 
mansoni + S. haematobium EST database (341544sequences; 86460946 residues) from 
the Sanger Institute (ftp://ftp.sanger.ac.uk/pub/pathogens/Schistosoma/). This searching 
was done to evaluate the potential presence of proteins of parasite origin.  
For Mascot searches, the peak lists were generated directly from QSTAR wiff 
files by Mascot Daemon v 2.2.2 (Matrix Science) with Sciex Analyst import filter 
options using the default parameters. The NCBInr Mus musculus database was searched 
using the following parameters: tryptic specificity, allowing two missed cleavages and a 
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tolerance on the mass measurement of 100 ppm in MS mode and 0.8 Da for MS/MS 
ions. The carbamidomethylation of Cys was set as a fixed modification, and Met 
oxidation and Asn/Gln deamidation were set as variable modifications. The significance 
threshold was set at 0.05. Only proteins for which there were two or more unique 
peptides matches were selected and shown in the results. 
For ProteinPilot searches, default parameters were used to generate the peak list 
directly from QSTAR wiff files of portal vein samples. The Paragon algorithm of 
ProteinPilot was used to search the NCBInr Mus musculus protein database with the 
following parameters: trypsin specificity and cys-alkylation. To avoid using the same 
spectral evidence in more than one protein, the proteins identified were grouped based 
on MS/MS spectra, using the Protein-Pilot Progroup algorithm. Thus, proteins sharing 
MS/MS spectra were grouped, regardless of the peptide sequence assigned. The protein 
within each group able to explain more spectral data with confidence is shown as the 
primary protein of the group. Only proteins with a Protein Pilot unused scored above 
1.3, which is equivalent to a protein confidence threshold greater than 95%, and for 
which there were at least one unique peptides matches with a confidence > 95% were 
selected and shown in the results. 
The relative abundance of a protein in the sample was quantified using the 
protein abundance index (PAI), which is defined as the number of observed peptides in 
the experiment divided by the number of observable tryptic peptides for each protein 
within a given mass range of the mass spectrometer employed [21]. PAI was modified 
exponentially to give emPAI, the exponential form of PAI minus one, which is directly 
proportional to the protein content in a sample [22]. The protein content in a particular 
sample was calculated as a percentage by dividing the emPAI value of a protein by the 
sum of all emPAI values in that sample multiplied by 100.  
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In the Results section, redundant identifications are eliminated from the lists of 
identified proteins, in each case choosing the protein hit with the highest score. When 
different, the emPAI values for a common hit in the two replicas were used to calculate 
the mean. 
 
2.7. Bioinformatic analysis of the proteins identified 
For the proteins identified, their biological function and cellular location were 
assigned according to the Gene Ontology database (http://amigo.geneontology.org), the 
SwissProt/UniProt databases (http://amigo.geneontology.org), the National Center for 
Biotechnology Information database (NCBI: http://www.ncbi.nlm.nih.gov/sites/entrez) 
and the literature. 
The presence of transmembrane helices was predicted using the TMHMM 
Server v. 2.0 at http://www.cbs.dtu.dk/services/TMHMM-2.0; the prediction of signal 
peptides with SignalP 3.0 [23]  at http://www.cbs.dtu.dk/services/SignalP and the search 
for glycosyl-phosphatidyl anchors with the big-PI Predictor [24] at 
http://mendel.imp.ac.at/sat/gpi/gpi server.html were also performed. 
 
2.8. Histochemical staining in portal vein sections. 
Biotin tagging of the vascular endothelium surface was verified by 
immunohistochemistry. Samples of perfused portal vein were fixed with 4% 
formaldehyde in PBS for 24 h and then dehydrated and embedded in paraffin following 
standard protocols. Microtome-cut 5 μm sections were placed on microscope slides, 
deparaffinised in xylene, and rehydrated. The biotin tag was detected in these sections 
by fluorescence, using a streptavidin-FITC probe, and by chromogenic staining using 
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streptavidin-horseradish peroxidase (HRP), 3,3'-diaminobenzidine (DAB) substrate and 
haematoxylin as counter stain. 
For immunofluorescence, hepatic portal vein sections were blocked with 1% 
BSA in PBS containing 0.05% Tween 20 (PBST) for 1 h at 37 ºC, and incubated with 
the streptavidin-Fluorescein isothiocyanate (FITC) (Sigma) diluted 1/500 in blocking 
buffer for 1 h at 37 ºC. Samples were washed five times with PBST and mounted in an 
antifade reagent (Prolong Gold, Invitrogen).  
For DAB-haematoxylin staining, sections were treated with 3% H2O2 for10 min 
to block the activity of the tissue peroxidase. After washing, samples were blocked with 
1% BSA in PBST and incubated with streptavidin-HRP (Sigma) diluted 1/1,000 in 
blocking buffer for 1 h at 37 ºC. Samples were washed three times, incubated with DAB 
for 3 min and counterstained with haematoxylin for 1.5 min. All incubations were 
performed in a humid chamber. 
 
2.9. SDS-PAGE and western blotting 
The composition of the total protein extract, the biotinylated protein and the 
efficiency of purification were checked by SDS-PAGE and western blot with 
streptavidin-HRP.  Samples of 5 µg of protein extract, the supernatant after capture, and 
resin-bound proteins were subjected to electrophoresis in 10% acrylamide gels. After 
running at 60 V, the gels were either stained with Coomassie brilliant blue or 
electrotransferred onto nitrocellulose membranes at 400 mA for 90 min. The 
membranes were blocked in 2% BSA, washed with PBST, and then incubated with 
streptavidin-HRP (Sigma) diluted 1/5,000 for 1h at room temperature. After washing, 
the reactive bands were developed using 4-chloro-1-naphthol as chromogen. 
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3. Results 
 
3.1. Verification of successful in vivo biotinylation 
The efficiency of vascular endothelium biotinylation after in vivo perfusion was 
assessed in portal vein samples taken from the mice from groups R1 and R2. This 
verification was performed by immunohistochemistry of paraffin sections of portal vein 
and by western blotting with streptavidin-HRP. 
The images of the portal vein sections stained with DAB and with FITC clearly 
showed that after perfusion the biotin was bound to components of the wall of the portal 
vein (Fig. 1). In the portal vein sections from the R0 mice, perfused only with PBS and 
dextran, no fluorescence or colorimetric staining was observed (not shown).  
Biotin labelling was also confirmed by western blotting, as can be observed in 
Fig. 2, which is described in the following section. 
 
3.2. Analysis of protein extracts and purification of biotinylated proteins. 
Total proteins were extracted from two independent batches from the R1 and R2 
groups and from one batch of the R0 group. 
After staining with Coomassie, the total protein extracts of the portal vein 
samples from the R0, R1 and R2 mice showed a similar band pattern, displaying many 
components, most of them with a molecular weight above 35 kDa (Fig. 2A). In the 
western blot of the protein extract from the R0 group (not perfused with biotin) two 
bands around 130 and 80 kDa were revealed (Fig. 2B). These molecular weights 
coincided with those of the enzymes pyruvate carboxylase (129,684 Da), propionyl 
CoA carboxylase (79,940 Da) and methylcrotonyl CoA carboxylase (79,369 Da). These 
proteins, which contain several biotin-binding sites, were abundantly identified in the 
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analysis by LC-MS/MS of this sample (next section). The pattern of biotinylated bands 
from the R1 and R2 groups was apparently similar to each other; up to 10 bands 
appeared with a molecular weight above 45 kDa. 
As can be observed in Fig. 2B, the biotinylated proteins were efficiently 
captured on the streptavidin-sepharose resin and the bulk of non-biotinylated proteins 
was washed away during the washing step. We performed digestion with trypsin while 
the proteins were still bound to the streptavidin-sepharose resin and subjected the 
resulting peptides to LC-MS/MS. 
 
3.3. Identification of biotinylated proteins 
A comparative proteomic analysis was performed between the samples of hepatic 
portal vein taken from the two groups of mice perfused with biotin: the group not 
infected with S. bovis (R1) and the group infected with this parasite four months before 
perfusion (R2). We also included the R0 control group (not infected, not perfused with 
biotin) in order to identify the proteins that might have been retained non-specifically in 
the resin. 
We classified the proteins identified in the portal vein according to currently 
available data concerning cellular location and their biological function and, based on 
their primary amino acid sequences, we also assessed the presence of a signal peptide, 
transmembrane domains and glycosyl-phosphatidyl anchors.  
Seventeen proteins were identified in portal vein samples from the control mice 
(R0). Together with the above-mentioned proteins which contain several biotin-binding 
sites, we also identified several keratins (or unknown protein similar to keratin), and one 
uncharacterized protein (gi|12842691), which was not identified in the samples from the 
R1 and R2 mice (Supplementary Table 1).  
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Table 1, 2 and 3 show the non-redundant proteins identified in the samples from 
the R1 and R2 groups. These results are the sum of the identifications performed with 
the Mascot and ProteinPilot searches in the two portal vein samples analyzed in each 
group of mice (4 mice/sample). The proteins which were also identified in the R0 
sample and the contaminating proteins such as trypsin, keratins, and proteins similar to 
keratins were not included in these lists.  
As a result, we identified a total of 127 non-redundant proteins: 73 in the portal 
vein of non-infected mice (R1) and 100 in those infected with S. bovis (R2). Of these 
proteins, 27 were identified only in the portal vein of the R1 group; 54 only in the R2 
mice (Table 2) and 46 in both groups of mice (Table 3). 
Considering the cellular location of the proteins identified in each group of mice, 
we observed that most of them -54.8% and 47.0% in the R1 and R2 groups, 
respectively- were annotated as externally-bound proteins or extracellular matrix 
proteins (Fig. 3A). As well as being the most numerous, these proteins proved to be the 
most abundant ones in both groups of mice, with an overall emPAI percentage of 59.2% 
in the R1 group and 75.0% in the R2 group (Fig. 3A). The proteins grouped in other 
categories (plasma membrane, cytoplasm, cytoskeleton, nucleus, other) were 
comparatively much less numerous and abundant, being the most pronounced difference 
the higher proportion of cytoskeletal proteins in the portal vein of the infected mice  
(16% in R2 versus 5.4% in R1). Proteins in other locations (ribosomal, mitochondrial) 
or unknown ontology were labelled “Other”. 
Analysis of the sequences of the identified proteins detected signal peptide in all 
the proteins classified as extracellular matrix and externally-bound secreted proteins. 
Likewise, all the proteins classified as being present in the plasma membrane contained 
one or several transmembrane domains, except the protein disulfide-isomerase 
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(P09103), which did not show any transmembrane domain. The assignment of a plasma 
membrane location to this last protein was done according to the Gene Ontology and the 
SwissProt/UniProt databases. No GPI anchors were identified in the sequence of any of 
the proteins (Tables 1, 2 and 3). 
Among the different biological functions found, cell adhesion molecules 
accounted for the largest category (Fig. 3B). In the samples from the infected mice (R2), 
as compared to the non-infected (R1), we identified a greater number of structural 
proteins (15.0 % protein number and 5.22 % emPAI for R2 versus 6.8 % protein 
number and 1.46% emPAI for R1), and of proteins involved in the immune response 
(8.0% protein number and 9.48 % emPAI for R2 versus 4.1% protein number and 3.1% 
emPAI for R1). 
 Proteins with oxido-reductase activity were only identified in the portal vein 
from the R2 mice (glutathione peroxidase 3, protein disulfide-isomerase and 
peroxiredoxin-1). As may be seen in Fig. 3B, the group of proteins that showed a 
clearly higher emPAI than the rest of the proteins were those involved in transport. This 
higher abundance was mainly due to haemoglobin, which showed 20.75% of emPAI in 
R1 and 25.11% in R2. Among the remaining categories, the most abundant proteins 
were those involved in cell adhesion, most of which are part of the extracellular matrix. 
Proteins having functions related to blood coagulation (fibrinogen alpha, beta and 
gamma), and proteins of unknown ontology were all included in the “Other” category 
(Fig. 3B). (Supplementary Tables 2 and 3 show the proteins classified according to their 
biological function) 
Fig. 4 summarizes the proteins identified only in the portal vein of non-infected 
(R1) or infected (R2) mice and the proteins identified in both groups of mice (R1+R2), 
classified according to their function and cellular location. 
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Among the 27 proteins identified only in the R1 mice, the most numerous were 
those included in the “Other” category, i.e., proteins with ribosomal or mitochondrial 
location or of unknown ontology; among the others, the most numerous were 
externally-bound proteins and nuclear proteins and, regarding function, the proteins 
with regulatory or catalytic activities (Table 1, Fig. 4).  
Among the 54 proteins identified only in the R2 group, the most numerous were 
cytoskeletal (26%) and externally-bound (17%) proteins, which were indeed the most 
abundant (9.47% emPAI). A large difference found in the R2 mice as compared to the 
R1 mice was the presence in the R2 group of immune response and oxido-reductase 
proteins and a notably higher amount of structural proteins (Table 2, Fig. 4).  
Regarding the proteins present in both samples, the highest proportion (39%) 
corresponded to proteins of the extracellular matrix, many of them involved in cell 
adhesion, and to blood components such as haemoglobin, fibrinogen, transferrin, etc, 
which proved to be the most abundant (Table 3, Fig. 4). 
The searching of the custom-made Schistosoma EST database with the samples 
from group R2 (infected with S. bovis) identified a total of 100 non-redundant hits. The 
subsequent BLAST analysis of these sequences allowed us to identify 64 proteins and 
28 hypothetical proteins (Supplementary Table 4).  To determine which of those 
proteins could be from S. bovis we applied the following requirements: (i) to be present 
in the excretion-secretion products and/or in the tegument of Schistosoma spp., and (ii) 
not to be identified in the Mus musculus NCBI database. Bearing in mind these 
requirementes, we found three tegumental proteins: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (Smp_056970), also present in the excretion/secretion 
products, Venom allergen-like (VAL) 7 protein (Smp_070240) and CD9-like protein 
Sm-TSP-1 (Smp_095630). 
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Discussion 
In schistosomiasis, recent research efforts have addressed the identification of 
the components involved in parasite-host relationships and have attempted to elucidate 
the mechanisms used by the parasite to ensure its survival in the host. Currently we 
have a fairly detailed knowledge of the parasite molecules that form part of the parasite-
host interface [20, 25-30], and of the mechanisms of modulation and evasion of the 
immune response [9]. Although scarcer, there is also information regarding the 
interaction of the parasite with the haemostatic system and about the anticoagulant and 
fibrinolytic properties of certain parasite proteins [10-12]. 
Regarding the interaction between schistosomes and the vascular endothelium, 
several authors have reported that along the course of infection the parasite can regulate 
the endothelial cell signalling and function to its own benefit, thereby ensuring its 
survival [13-18]. However, the data in this particular field of schistosome research are 
scant, and information about the proteins expressed on the endothelial surface along 
infection is lacking, as is information about the parasite molecules that might be 
involved in the regulation of the functioning of the endothelium.  
In order to improve our knowledge of the mechanisms involved in the regulation 
of the vascular endothelium by schistosomes, here we were prompted to identify the 
changes induced by adult worms of S. bovis in the proteome of the endothelial surface 
of the host portal vein. 
To conduct this study, we used a methodology that would allow the purification, 
identification, and relative quantification of the cell surface proteins after selective 
labelling in vivo. This method has been used in several disease models, such as tumours, 
Alzheimer’s disease and diabetic nephropathy, in order to establish an atlas of vascular 
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proteins in health and disease [31-36]. However, this is the first time that this method 
has been used in a study aimed at establishing the differential molecular profile between 
a healthy and pathologic status in an infection due to an intravascular pathogen. 
The application of this methodology in an in vivo model has important 
advantages as compared to similar studies carried out in vitro. Studies involving 
endothelial cell cultures have important limitations, mainly due to the phenotypic 
heterogeneity of endothelial cells related to their anatomical location and to the 
regulation exerted by the tissue microenvironment in the protein expression of 
endothelial cells, a regulation that cannot be duplicated in standard cell cultures [6]. For 
example, in a comparative proteomic analysis of endothelial cell surface membranes 
isolated from rat lug versus cultured cells, Durr et al. [37] found that only 51% of the 
integral membrane and plasma membrane-associated proteins identified were expressed 
in common. 
The isolation of biotinylated proteins from mouse hepatic portal vein by 
streptavidin-sepharose resin followed by LC-MS/MS analysis led to the identification of 
127 non-redundant proteins, of which 100 were identified in the vascular endothelium 
of S. bovis-infected mice and 73 in non-infected mice. As in other studies addressing the 
aortic artery and the lung microvascular endothelial cell surface, most of the proteins 
identified were involved in cell adhesion including externally-bound proteins, 
components of the extracellular matrix and proteins associated with the plasma 
membrane [33, 37]. However, here we also found that one fraction of the proteins 
identified were categorized as intracellular (20.0% in the R1 group and 34.0% in the R2 
group). This was somewhat unexpected since, at least theoretically, labelling with biotin 
must be limited to the proteins of the cell surface. Notwithstanding, is has been 
observed that the sulfo-NHS-LC-biotin label could pass through the cell membrane and 
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could label intracellular proteins as well [38]. In addition, Durr et al [37] suggested the 
possibility that some of these proteins simply reside in more than one subcellular 
location. It is not unusual for proteins initially categorized as organelle-specific to be 
discovered later elsewhere in the cell. In fact, three of the proteins identified here are 
examples of this. Protein disulfide-isomerase, commonly classified as an endoplasmic 
reticulum (ER) protein, has been detected in sinusoidal rat liver plasma membranes 
[39]. The 78 kDa glucose-regulated protein is a stress protein belonging to the Hsp70 
multigene family that is located inside the ER, but also expressed in the cell membrane 
and present in the peripheral circulation of humans [40]. Elongation factor-1 alpha is 
primarily known as a component of the protein synthesis machinery but also has a less 
well-known function in cytoskeletal reorganization [41]. Finally, it cannot be discarded 
that the worms would have caused some injury to the endothelial cells resulting in 
intracellular protein biotinylation. 
Some well known surface receptors including CD146, CD91, vascular adhesion 
protein and integrin  were identified, but we were unable to detect other known markers 
of endothelial surfaces such as eNOS, VE-cadherin, E-selectin, ICAM-1 or PECAM-1. 
As remarked by Arjunan et al. [42], it is possible that the level of expression of these 
molecules in the cell membrane might be too low to be detected, being masked by other 
much more abundant proteins, such as those found in  blood  or the components of the 
extracellular matrix. It should be also brought in mind that since the biotinylation 
reagent interacts with primary amine groups (lysine side-chains or protein N-termini), 
the lack of primary amines in the extracellular domain of membrane spanning proteins, 
as well as inaccessibility due to the three-dimensional structure of the protein, may 
prevent efficient biotinylation [31]. 
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Comparative proteomic analysis of endothelial cell surface proteins isolated from 
the portal vein of mice infected and non-infected wit S. bovis revealed obvious 
differences. A total of 27 proteins were uniquely expressed in the portal vein of mice 
from the R1 group (non-infected) and 54 exclusively expressed in that of the R2 
(infected) animals. However, given the low score and the reduced number of unique 
peptides identified (PN) for some of these proteins (Table 1 and 2), it is very possible 
that some of the differences observed in the protein composition between R1 and R2 
groups could in fact represent quantitative differences in the expression level of the 
proteins, such that the least abundant would be below the threshold for detection by MS.  
Nevertheless clear differences in the protein composition between both groups of 
mice were as follows: (i) a greater number of cytoskeletal proteins in the samples from 
the infected mice (15 in R2 versus 4 in R1); (ii) a greater number of proteins related to 
the immune response in the infected mice, mainly immunoglobulins  (8 in R2 versus 3 
in R1), and (iii) the identification only in the infected mice of three proteins with 
oxidoreductase activity (peroxiredoxin, glutathione peroxidase and protein disulfide-
isomerase). 
The cytoskeleton not only serves for the maintenance of cellular shape but also 
plays roles in other cellular functions, including cellular and organelles movement, cell 
division, endocytosis and as a mediator of inflammation [43]. Regarding infections by 
schistosomes, in vitro studies have shown that pulmonary schistosomula attach to the 
lung endothelium through at least one endothelial cytoskeleton component [13].  It is 
therefore possible that adult worms could use the same mechanism to become attached 
to the wall of the portal vein and mesenteric vessels, which would account for the 
higher expression of cytoskeletal proteins in the infected animals. Further studies would 
be necessary to confirm this. 
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The higher number of immunoglobulins identified on the surface of the vascular 
tissue of the infected animals is a clear sign of the immune response induced by the 
infection. 
Peroxiredoxin and glutathione peroxidase are two anti-oxidant enzymes that may be 
involved in protection against the reactive oxygen species released by host immune 
effector cells. Glutathione peroxidase is an enzyme that can be secreted, and 
peroxiredoxin, although this is mainly found in the cytosol and lacks a signal peptide, 
recent studies have demonstrated that it can be possibly secreted via a non-classic 
secretory pathway [44]. These molecules exposed on the endothelial surface could play 
a crucial role in the prevention of host responses to pathogen products and protect host 
tissues from the reactive oxygen species produced during the anti-schistosome immune 
response [45, 46]. 
Protein disulfide-isomerase is a dithiol-disulfide oxidoreductase chaperone of the 
thioredoxin superfamily that plays multiple roles in redox signalling and homeostasis. 
This protein is expressed in the ER and also on the surface of endothelial cells, where it 
exerts an inhibitory effect on coagulation through the regulation of tissue factor [47, 
48]. Regarding these functions, another protein expressed in the vascular endothelium 
of infected mice that also inhibits the procoagulant activity of the tissue factor is the78-
kDa Glucose-Regulated Protein (GPR78) [49]. Taking into account the biology of the 
parasite, it is not surprising that schistosomes are able to regulate the endothelium 
promoting anticoagulant conditions. It has been shown that the parasite itself has 
molecules with anticoagulant, profibrinolytic and vasodilator activity [11, 12 50]. 
Evidently, the ability to elude coagulation or promote vasodilatation would permit the 
worm free mobility in the vasculature without eliciting harmful ischemia and hypoxia, 
which could damage them [50].  
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Regarding the three proteins of possible S. bovis origin identified in the infected 
mice samples, namely, GAPDH, Sm_VAL-7 and Sm_TSP-1, there is no information 
about their possible interaction with the vascular endothelium. However, since all of 
them are part of the host-schistosome interface [25, 27, 51, 52], it cannot be ruled out 
that they might play some kind of regulation on the endothelium. GADPH is a 
multifunctional protein with functions other than glycolysis including regulation of 
cellular response to oxidative stress and fibrinolysis [53, 54]. The SmVAL is a member 
of the SCP/TAPS (Sperm-Coating Protein/Tpx-1/Ag5/PR-1/Sc7) protein superfamily, 
with a signal peptide allowing it to be secreted to interact with their immediate 
environment, which may be important in host-pathogen interactions [52]. Tetraspanins 
have been identified on the surface of S. mansoni and their functions there are as yet 
unknown [51]. Nevertheless, bearing in mind that endothelial cells can express many 
tetraspanins of great importance in endothelial cell biology it is possible that we could 
be dealing with a protein from the host [55]. Obviously, further studies are needed to 
confirm if these three parasite proteins play some kind of regulation on the vascular 
endothelium of the host. 
In sum, the present work provides the first data on the proteome of the endothelial 
surface of the mouse portal vein, and identifies some of the changes induced in it after 
infection by S. bovis. 
Further studies should shed further light on these and other S. bovis-induced 
endothelial changes, and could pinpoint the parasite molecules involved in the 
regulation of the vascular endothelium.  Since these molecules could be essential for 
parasite survival, they could constitute potential targets for the development of new 
drugs and anti-schistosome vaccines. 
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Figure legend. 
Figure 1. Biotinylation of the hepatic portal vein endothelium in the mice perfused with 
biotin. Paraffin sections of the portal vein. (A) Fluorescence staining with streptavidin-
FITC. (B) Chromogenic staining using streptavidin-horseradish peroxidase (HRP), 3,3'-
diaminobenzidine (DAB) substrate and haematoxylin as counter stain. The right images 
show the zones depicted in the left panels in greater detail. The biotinylation signals in 
infected and non-infected mice were similar. These images are representative of both 
groups of mice.  
Figure 2. Analysis of the extracted proteins from mouse portal vein. The vascular portal 
vein of infected (R2) and non-infected (R1) mice were biotinylated with Sulfo-NHS-
LC-biotin via systemic perfusion. The group of non-infected mice (R0) were perfused 
only with PBS and dextran. (A) Coomassie-stained SDS-PAGE of the protein extracts 
from portal vein samples from the mice in the groups R0, R1 and R2. (B) Western blot 
analysis of the biotin-labelled proteins in the total protein extracts, in the supernatants 
after capture (unbound proteins) and in the fraction of proteins bound to the 
streptavidin-sepharose resin. 
Figure 3. Proteins identified in the portal vein of the infected (R2, white bars) and non-
infected (R1 black bars) mice. The proteins are classified in categories according to 
their cellular location (A) and biological function (B). % Protein number is the ratio 
between the number of proteins identified in each category with respect to the total 
number of proteins identified. The emPAI percentage of each category is the sum of the 
% emPAI of each protein. 
Figure 4. Classification of the proteins differentially identified in each group of mice by 
cellular location and biological function. (R1) Proteins identified in the portal vein from 
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non-infected mice only. (R2) Proteins identified in portal vein from Schistosoma bovis-
infected mice only. (R1 and R2) Proteins identified simultaneously in both groups of 
mice. Pie charts represent the percentages of proteins in each category. Numbers in 
brackets indicate the % emPAI for each category calculated as the sum of the % emPAI 
of all the proteins in that category. In R1and R2 charts, both values of % emPAI are 
given (R1- R2, respectively). 
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Table 1.  Proteins identified only in the portal vein endothelium of uninfected mice 
(R1).  
  
SwissProt 
locus 
NCBI locus Protein 
% 
emPAI1 
Score 
(Mascot/Pilot)2 
PN 
(Mascot/Pilot)
3 
Predicted 
TMs4 
Signal 
peptide 
Externally bound (Secreted, blood) 
Q19LI2 124486702 
Alpha-1B-glycoprotein 
precursor 
0.36 79/3.07 2/2 0 yes 
Q64285 6753406 Bile salt-activated lipase 0.6 64 2 0 yes 
P23953 192854 Liver Carboxylesterase 0.55 50/2.09 1/2 0 yes 
Q6P8U6 37674236 
Pancreatic triacylglycerol 
lipase 
0.36 66/4.47 1/3 0 yes 
Extracellular matrix 
     
Q64739 841122 Collagen alpha-2(XI) _ 3.25 2 1 yes 
Q62000 6679166 Mimecan precursor  1.2 140/5.77 4/3 0 yes 
P82198 74215223 Transforming growth factor  _ 1.54 1 0 yes 
Plasma membrane 
     
Q8R420 19918916 
ATP-binding cassette 
transporter  
0.18 59 3 9 no 
Q60849 973182 CD98 heavy chain 0.66 67/2.25 2/1 1 no 
Q9EPB2 9954443 Natural killer cell receptor  _ 44 2 1 no 
Cytoplasm 
     
Q9QZ05 12847465 
Eukaryotic translation 
initiation factor 2-alpha 
kinase 4 
0.48 78/8.53 3/5 0 no 
D3Z6P0 109731005 
Protein disulfide-isomerase 
A2 
0.72 123/2.91 3/2 0 yes 
Q6PFX9 87239974 Tankyrase-1 _ 54 2 0 no 
Cytoskeleton 
     
A2ARZ3 123232783 
Fibrous sheath-interacting 
protein  
_ 65 2 0 no 
D3Z667 124486773 Dynein heavy chain 2 _ 52 3 0 no 
Nucleus 
     
Q69ZA1 124486698 Cyclin-dependent kinase   _ 37 2 0 no 
O08550 115495457 Histone MLL4 _ 41 2 0 no 
Q8VCQ3 12833067 
Nuclear receptor-binding 
factor  
_ 47 2 0 no 
O35134 2330007 RNA polymerase I  _ 44 2 0 no 
Miscellaneous or unknown ontology 
     
P47911 38571759 60S ribosomal protein L6 0.6 44 2 0 no 
Q6GQX6 67906181 
Ankyrin repeat and SAM 
domain-containing protein 6 
0.24 76 3 0 no 
_ 14277826 
Chain B, Crystal Structure of 
G3-519 
1.47 51 2 0 no 
Q924L1 19527322 
LETM1 domain-containing 
protein 1  
_ 42 2 1 yes 
_ 148708988 mCG20427  _ 50 3 0 no 
_ 148709576 mCG66490 _ 48 2 6 no 
Q52KE6 62871717 Pgbd5 protein _ 2.00 1 0 no 
Q3V0M1 85701949 Uncharacterized protein  0.28 53 2 0 no 
1
% emPAI (percentage of exponentially modified protein abundance index) was calculated by dividing 
the emPAI value of a protein by the sum of all emPAI values multiplied by 100. 
2
Scores with decimals belong to Protein Pilot-derived identification; scores without decimal identification 
correspond to MASCOT-derived identifications. 
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3
PN. Number of unique peptides identified. Protein Pilot-derived identifications show the number of 
peptides identified with a confidence > 50%. 
4
TMs, Nº of transmembrane domains  
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Table 2. Proteins identified only in the portal vein endothelium of mice infected with 
Schistosoma bovis (R2). 
SwissProt  
locus 
NCBI 
locus 
Protein 
% 
emPAI1 
Score 
(Mascot/Pi
lot)2 
PN 
(Mascot/Pi
lot)3 
Predicted 
TMs4 
Signal 
peptide 
 Externally bound (Secreted, blood)  
Q3V2G1  74203337 Apolipoprotein A-I 0.89 117/2.27 3/1 0 yes 
P46412  15011841 Glutathione peroxidase 3 1.09 92/2.06 2/2 0 yes 
Q61646  8850219 Haptoglobin precursor 0.7 80/2.34 2/2 0 yes 
P28666  112914 Murinoglobulin 0.15 68/2.97 2/2 0 yes 
_ 148589114 
Anti-human c-myc monoclonal 
antibody 9E10  
0.23 104 4 0 yes 
_ 1421599 
Chain L, Idiotype-Anti-
Idiotype Fab Complex 
2.64 134 5 0 no 
_ 110077  Ig gamma-1 chain C region  0.47 105 3 0 no 
_ 110434 Ig kappa ligth chain  2.6 139/5.01 5/4 0 no 
_ 34785917 Igh protein 0.7 121/12.6 4/7 0 yes 
 Extracellular matrix  
P28481 30410850 Collagen alpha-1(II)  _ 41/2.82 3/2 0 yes 
B1AWB9 223461042 Collagen alpha-1(V) _ 2.00 1 1 yes 
Q61554 726324 Fibrillin-1  0.23 154 5 0 yes 
F8VQ43 117647249 Laminin alpha 2 _ 2.00 1 0 yes 
Q62009 7657429 Periostin  0.43 99/3.32 3/3 0 yes 
 Plasma membrane   
P20029 1304157 
78 kDa glucose-regulated 
protein  
0.35 68 2 1 yes 
Q91ZX7 49942 
Alpha-2-macroglobulin 
receptor (CD91) 
_ 39 2 1 yes 
Q8R2Y2 10566953 
Cell surface glycoprotein 
MUC18 
0.35 85 2 1 yes 
P09103 129729 Protein disulfide-isomerase 0.23 122 4 0 yes 
Q8C310  27229187 
Roundabout homolog 4 
precursor  
_ 46 2 2 yes 
 Cytoplasm  
O54774  6671565 AP-3 complex subunit delta-1 _ 45 2 0 no 
Q8VDR9 122065169 
Dedicator of cytokinesis 
protein 6 
_ 42 2 0 no 
A2APV2  29126933 Formin-like protein 2 _ 42 2 0 no 
Q6P5H2 50363232 Nestin _ 52 2 0 no 
P35700 6754976 Peroxiredoxin-1  _ 47 2 0 no 
Q99K08 13529638 Phosphofructokinase _ 53 3 0 no 
Q6P9N8 40254203   
Trafficking protein, kinesin 
binding 2 
_ 56 2 0 no 
Q8K466  22023780 TSP50  _ 38 2 0 yes 
A2ALK8 218505829 
Tyrosine-protein phosphatase 
non-receptor type 3  
_ 45 2 0 no 
 Cytoskeleton   
P59242 27503680 Cingulin 0.94 62 2 0 no 
Q3UJV1 75677484 
Coiled-coil domain-containing 
protein 61  
_ 54 3 0 no 
Q45VK7 72534792 Dynein 2 heavy chain 1  _ 42 2 0 no 
Q91XQ0 153792273 Dynein heavy chain 8  0.35 50 3 0 no 
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B1AR51 153791933 Dynein heavy chain 9 _ 66 3 
 
no 
Q91ZU6 15077863 Dystonin _ 70 4 0 no 
_  90508 Gelsolin 0.31 50 2 0 no 
Q60575 407339 Kinesin-like protein  _ 39 2 0 no 
Q8VDD5 17978023  Myosin II-A 0.12 103/2.28 4/1 0 no 
Q9QXS1  40849908 Plectin 1  _ 67 4 0 no 
Q8BUJ6 77812 Titin isoform N2-A _ 106 7 0 no 
Q9JHJ0  8394460 Tropomodulin-3 _ 46 2 0 no 
P05213 202210 Tubulin alpha-1B chain 0.23 54 2 0 no 
P20152 55291 Vimentin 0.35 196 5 0 no 
Nucleus 
E9Q616 61743961 
AHNAK nucleoprotein 
isoform 1  
0.04 86 3 0 no 
Q6ZPV2 26333853 DNA helicase INO80 _ 42 2 0 no 
P84228 51301 Histone H3.2 1.9 113/2 3/1 0 no 
P50540 6754766 
Max-interacting protein 1 
isoform a  
_ 47 2 0 no 
Q61312 1154873 
Transcription factor AP-2 
gamma 
0.82 49 2 0 no 
Miscellaneous or unknown ontology 
Q61315 12643510 
Adenomatous polyposis coli 
protein 
_ 48 3 0 no 
_ 148696491 mCG11496  _ 46 3 1 no 
_ 148667581 mCG115458, isoform CRA_a  _ 53 3 0 no 
_ 148704071 mCG141014  _ 50 2 0 no 
_ 148672709 
Phospholipase A2, group VI, 
isoform CRA_a 
_ 45 2 0 no 
Q8BFU3 26324710 RING finger protein 214 _ 53 2 0 no 
_ 148687286 
Zinc finger, CW type with 
PWWP domain 1  
_ 49 2 0 no 
1
% emPAI (percentage of exponentially modified protein abundance index) was calculated by dividing 
the emPAI value of a protein by the sum of all emPAI values multiplied by 100. 
2
Scores with decimals belong to Protein Pilot-derived identification; scores without decimal identification 
correspond to MASCOT-derived identifications. 
3
PN, Number of peptides identified. Protein Pilot-derived identifications show the number of peptides 
identified with a confidence > 50%. 
4
TMs, Nº of transmembrane domains. 
. 
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Table 3. Proteins identified in the portal vein endothelium of both groups of mice, the 
uninfected (R1) and the infected with Schistosoma bovis (R2). 
SwissPro
t locus 
NCBI 
locus 
Protein 
% emPAI 1 Score (Mascot/Pilot)2  
PN 
(Mascot/Pilot)
3 
Predicte
d TMs4 
Signal 
peptid
e 
R1 R2 R1 R2 R1  R2 
Externally bound (Secreted, blood) 
P07724 26340966 Albumin 4.81 4.50 770/25.65 
1000/32.1
9 
15/19 20/23 0 no 
P07758 6678079 
Alpha-1-
antitrypsin 1-1 
precursor  
1.92 0.27 204/8.39 82/6.77 5/6 3/4 0 yes 
Q61838 199086 
Alpha-2-
macroglobulin 
0.24 0.31 98/1.59 285/4.44 2/3 8/4 0 yes 
P01027 1352102 
Complement 
C3 
0.12 0.35 73/7.7 291/10.9 3/5 9/9 1 yes 
P06909 116132 
Complement 
factor H 
_ 0.08 2.00 49/1.70 1 1/1 0 yes 
P07759 50442 Contrapsin  0.9 0.89 149 150/3.00 4 3/3 0 yes 
Q8K0E8 33859809 
Fibrinogen beta 
chain precursor  
0.72 1.28 162/3.75 342/8.87 4/2 8/7 0 yes 
Q8VCM
7 
19527078 
Fibrinogen 
gamma chain 
precursor  
2.29 1.13 248/5.4 252/6.18 6/5 7/6 0 yes 
Q99K47 33563252 
Fibrinogen, 
alpha 
polypeptide 
isoform 2  
1.8 1.4 259/9.79 402/12.79 8/6 11/9 0 yes 
P01942 122441 
Hemoglobin 
subunit alpha 
7.52 6.83 127/12.79 189/12.46 4/9 6/9 0 no 
A8DUP3 12846616 
Hemoglobin 
subunit beta-1  
13.2
3 
18.2
8 
284/11.21 442/16.98 7/9 9/10 0 no 
Q91X72 1881768 Hemopexin  0.36 1.09 50 280/8.31 2 9/5 0 yes 
_ 3688704 
Immunoglobuli
n heavy chain 
variable region 
2.95 2.41 61 96/2.00 2 3/1 0 no 
P00688 
11160746
7 
Pancreatic 
alpha amylase 
0.72 1.24 125/6.38 275/9.73 3/4 6/7 0 yes 
Q921I1 74178118 Serotransferrin  1.68 2.72 254/13.52 682/22.57 8/8 15/12 0 yes 
Extracellular matrix 
Q99MQ4 27754118 
Asporin 
preproprotein  
0.96 0.62 201 140 3 3 0 yes 
P28653 348962 Biglycan  2.1 1.78 204/6.55 218/8.00 5/4 6/4 0 yes 
O88493 3236370 
Collagen alpha-
3 (VI) 
0.42 0.66 393/16.9 867/16.5 10/11 23/12 1 yes 
Q04857 6753484 
Collagen alpha-
1(VI)   
0.18 1.05 87/6 205/15.83 2/5 7/13 0 yes 
P08122 556299 
Collagen alpha-
2 (IV)   
0.12 0.07 75/4.05 63/2.06 2/2 1/2 1 yes 
Q02788 49809 
Collagen alpha-
2(VI)  
_ 2.23 95 332/4.28 3 9/2 0 yes 
P11087 470674 
Collagen pro-
alpha-1(I)   
1.2 2.69 411/111.4 451/90.19 9/60 11/53 0 yes 
Q01149 50489 Collagen pro- 1.5 2.58 461/111.4 386/72.4 9/60 9/40 0 yes 
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alpha-2(I)   6 
Q80X19 30420885 
Collagen alpha-
1(XIV)  
0.3 0.23 193/6.6 44/2.00 5/4 1/1 1 yes 
Q7TT32 
30851550
  
Collagen alpha-
1(III)  
_ 0.59 57/59.17 79/56.1 2/31 3/31 0 yes 
P28654 6681143  
Decorin 
preproprotein  
3.67 3.45 358/14.81 423/19.72 11/10 11/11 0 yes 
P11276 74218046 Fibronectin 1 _ 0.08 4.52 42 2 3 0 yes 
Q61292 2497599 
Laminin 
subunit beta-2  
0.18 0.08 87 71 3 3 0 yes 
P02468 126370 
Laminin 
subunit 
gamma-1 
0.3 0.16 172 2.73 6 3 0 yes 
P51885 1168179 Lumican  3.07 2.48 196/10.07 260/8.51 5/6 6/7 0 yes 
P10493 53384 Nidogen-1 0.12 0.19 53/4.45 80/2.04 2/2 2/1 0 yes 
B1B0C7 
12289111
4 
Perlecan  0.12 0.12 135/6.55 269/14.77 3/4 7/12 0 yes 
Q9JK53 
22960892
0 
Prolargin  2.64 3.07 180/6.42 358/5.82 5/5 8/5 0 yes 
Plasma membrane 
Q64314 19526792 
Hematopoietic 
progenitor cell 
antigen CD34 
isoform 2 
precursor  
0.55 _ 40 50 3 3 1 yes 
P09055 762977 Integrin beta-1 0.42 0.16 90/1.49 93 3/1 2 1 yes 
_ 6754382 
Leukocyte 
surface antigen 
CD47 
_ 0.35 1.52 104/2 2 1/1 5 yes 
A2AGL3 
12321026
4 
Ryanodine 
receptor 3  
_ _ 39 9 2 3 6 no 
O70423 6753066 
Vascular 
adhesion 
protein 1 
_ 0.31 5.81 144/6.66 4 3 1 no 
Cytoplasm 
P10126 50797 
Eukaryotic 
elongation 
factor 1 
0.84 1.43 225 292/9.38 5 6/7 0 no 
E9Q624 
51988896
  
Zinc finger 
protein 644 
_ _ 58 58 3 2 0 no 
Cytoskeleton 
P68033 387090 Actin 0.5 1.79 134/5.79 221/11.32 4/5 5/8 0 no 
Q8R384 20070691 Myh11 protein 0.36 0.12 109 118 5 5 0 no 
Nucleus 
Q8CGP0 76826886 Histone H2B  _ 
_0.8
9 
1.53 55/3.52 1 1/2 0 no 
P62806 51311 Histone H4  4.15 2.68 112/2.15 124/3.22 2/1 3/2 0 no 
Miscellaneous or unknown ontology 
Q6A074 50510473 
mKIAA0400 
protein 
_ _ 85 73 3 3 0 no 
Q99MV3 
11872233
8 
Testis 
expressed gene 
15  
__ _ 41 39 2 2 0 no 
1
% emPAI (percentage of exponentially modified protein abundance index) was calculated by dividing 
the emPAI value of a protein by the sum of all emPAI values multiplied by 100. 
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2
Scores with decimals belong to Protein Pilot-derived identification; scores without decimal identification 
correspond to MASCOT-derived identification. 
3
PN, Number of peptides identified. Protein Pilot-derived identifications show the number of peptides 
identified with a confidence > 50%. 
4
TMs,  Nº of transmembrane domains. 
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Highlights  
 
 
 
- We have isolated mouse endothelial cell surface proteins by in vivo 
biotinylation. 
- We provide the first data on the proteome of the endothelial surface of mouse 
portal vein. 
- We identify changes in protein expression in portal vein endothelium induced 
by S. bovis. 
